In May 2009, the Air France KLM Group and Delta Air Lines signed an agreement to jointly operate their trans-Atlantic routes, thereby sharing revenues and costs in a joint venture. The relationship was expanded in July 2010 to include Alitalia and now generates annual revenues estimated at more than $10 billion. Together, Delta-Air France-KLM-Alitalia operate 248 daily flights between 26 North American gateways and 33 cities in Europe alone. Representing 26% of the capacity across the Atlantic, the joint venture is the natural trans-Atlantic leader. Most importantly, the joint venture partners provide customers with a wider choice of flights and more convenient flight times through their vast network centered on 6 major hubs, including Atlanta Hartsfield-Jackson. Worldwide, the group serves close to 300 destinations in North America, 200 destinations in Europe, Asia and Latin America, and offers competitive fares, as well as a seamless travel experience throughout the joint venture network, from lounges to transferring between flights, to providing the best-in-class service to their customers. For more information visit: www.delta.com, www.airfrance.com, www.klm.us.
Celebrating creativity, chaos and teamwork since 2001, MailChimp is an email marketing service provider to manage contacts, send marketing emails and track results. It has more than 8 million users that collectively sends over 10 billion emails through the service each month. http://mailchimp.com/
Nissan is among the world’s leading car manufacturers, supplying the automobile market across the five continents. The multinational Japanese company has developed a partnership with French automaker Renault in 1999.Today, the automobile company continues to expand its international market and participates in shaping our future by developing groundbreaking technological products.
Rubicon Global is a waste and recycling company focused on sustainability. The Atlanta-based company was founded on a bold idea: to disrupt the waste and recycling industry and create less expensive, more sustainable solutions. https://www.rubiconglobal.com
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.